BAZ2B
MOLECULAR TARGETbromodomain adjacent to zinc finger domain 2B
BAZ2B (bromodomain adjacent to zinc finger domain 2B) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting BAZ2B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | DEAD-box RNA Helicases | 0.69 | 1 |
| 2 | Thioctic Acid | 0.69 | 1 |
| 3 | egcg | 0.69 | 1 |
| 4 | Hesperidin | 0.69 | 1 |
| 5 | Luteolin 5,7,3',4'-tetrahydroxy-flavone, | 0.69 | 1 |
| 6 | Methylene Blue | 0.69 | 1 |
| 7 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
| 8 | Rosmarinic Acid | 0.69 | 1 |
| 9 | Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). | 0.69 | 1 |
| 10 | ag490 | 0.69 | 1 |
| 11 | Aurintricarboxylic Acid | 0.69 | 1 |
| 12 | Carvedilol | 0.69 | 1 |
| 13 | cefaclor | 0.69 | 1 |
| 14 | Cefotetan | 0.69 | 1 |
| 15 | Ciclopirox | 0.69 | 1 |
| 16 | Clotrimazole | 0.69 | 1 |
| 17 | Demeclocycline | 0.69 | 1 |
| 18 | Ethoxyquin Antioxidant; also | 0.69 | 1 |
| 19 | Fusaric Acid | 0.69 | 1 |
| 20 | Hexachlorophene | 0.69 | 1 |
| 21 | Metergoline | 0.69 | 1 |
| 22 | Methyldopa | 0.69 | 1 |
| 23 | mg624 | 0.69 | 1 |
| 24 | Nicardipine | 0.69 | 1 |
| 25 | Niflumic Acid | 0.69 | 1 |
| 26 | Oxytetracycline | 0.69 | 1 |
| 27 | Picloram | 0.69 | 1 |
| 28 | Promethazine | 0.69 | 1 |
| 29 | Reserpine | 0.69 | 1 |
| 30 | Thioctic Acid | 0.69 | 1 |
| 31 | Thioridazine | 0.69 | 1 |
| 32 | triflupromazine hydrochloride | 0.69 | 1 |
| 33 | Tryptophan | 0.69 | 1 |
About BAZ2B as a Drug Target
BAZ2B (bromodomain adjacent to zinc finger domain 2B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented BAZ2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
BAZ2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.